Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Researchers identify the target structures for T-cell response against SARS-CoV-2

Our immune system can efficiently fend off viral diseases. Two types of immune cells play an important role in this process: The T-cells, which firstly can directly destroy virus-infected cells and secondly enable the formation of efficient, virus-neutralizing antibodies by B-cells.

30 Sep 2020

SARS-CoV-2 D614G variant enhances infectivity, replication and transmission

Researchers in the United States and Japan have conducted a study showing a common mutation in the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) - the agent that causes coronavirus disease 2019 (COVD-19) - enhances the infectivity, replication, and early transmission of the virus.

30 Sep 2020

Newly developed fusion protein could improve COVID-19 research

Researchers at the Paul Scherrer Institute in Switzerland have developed a high-quality recombinant virus protein that could be applied in the development of vaccines against the 2019 novel coronavirus (2019-nCoV) and in the detection of novel viruses or antibodies.

30 Sep 2020

Researchers identify a new method to produce miniaturized antibodies

Researchers at the University of Bath in the UK and biopharma company UCB have found a way to produce miniaturized antibodies, opening the way for a potential new class of treatments for diseases.

30 Sep 2020

New graphical tool to identify potent neutralizing antibodies against SARS-CoV-2

A new study by researchers at the Indian Institute of Science and the University of Queensland and published on the preprint server medRxiv in September 2020 discusses using a novel tool to identify the most effective among currently known anti-SARS-CoV-2 NAbs.

29 Sep 2020

Using new technology to study antibody responses in SARS-CoV-2-infected individuals

Using a technology called VirScan to study coronavirus antibody responses in a large cohort of SARS-CoV-2-infected and control individuals, researchers identified epitopes recognized by a large fraction of COVID-19 patients, epitopes cross-reactive with antibodies developed in response to other human coronaviruses, and 10 epitopes likely recognized by neutralizing antibodies.

29 Sep 2020

Self-collection of blood for COVID-19 antibody testing may be a reliable and easy alternative

Some evidence suggests that IgGs appear at 6-15 days after infection and may persist for months. However, large-scale testing over time is required to understand the immunological response to COVID-19 with greater accuracy. A recent pilot study published on the preprint server medRxiv in September 2020 reports the use of self-collected capillary blood for serology, with highly promising results.

29 Sep 2020

Novel immunotherapy platform can connect mussel adhesive proteins to the antibodies

Antibody-based immunotherapy is one of treatment options for cancer immunotherapy by modulating our immune system with therapeutic antibodies.

29 Sep 2020

Antibody improves progression-free survival in patients with advanced prostate cancer

An antibody for treating advanced prostate cancer improves progression-free survival in patients with metastasised, castration-resistant prostate cancer.

29 Sep 2020

SARS-CoV-2 re-infection is real but rare: Case study

Now, American researchers have looked at all reported cases of re-infection and the possible reasons behind them. Their study titled, “Re-infection with SARS-CoV-2 and Failure of Humoral Immunity: a case report,” is published online on the preprint server medRxiv in September 2020.

28 Sep 2020

Cincinnati Children's research leads to approval of new drug for hypereosinophilic syndrome

Following two decades of research on a group of rare diseases called hypereosinophilic syndrome at Cincinnati Children's Hospital Medical Center, the U.S. Food and Drug Administration has approved the drug Nucala (mepolizumab) for use in the treatment of patients with hypereosinophilic syndrome.

28 Sep 2020

New agreements to ensure all countries have fair access to COVID-19 rapid diagnostic tests

A set of agreements to make available, for low and middle-income countries, affordable, high-quality COVID-19 antigen rapid tests were today announced by the Access to COVID-19 Tools (ACT) Accelerator.

28 Sep 2020

J&J's COVID-19 vaccine shows potent immune response in phase 2 human trial

A multicenter phase 1/2a randomized, double-blinded, placebo-controlled clinical trial has been conducted recently to evaluate the safety, reactogenicity, and immunogenicity of a non-replicating adenovirus-based vaccine, namely Ad26.COV2.S against severe acute respiratory coronavirus 2 (SARS-CoV-2) infection.

28 Sep 2020

Hamsters and ferrets clear low dose SARS-CoV-2 infection in 14 days

A recent study by French researchers has demonstrated that experimental exposure to severe acute respiratory coronavirus 2 (SARS-CoV-2) is capable of inducing mild infection in hamsters and ferrets within 7 – 10 days of exposure. However, the infection completely resolves within 14 days. The study is currently available on the bioRxiv preprint server.

28 Sep 2020

Early introduction of gluten may be an effective celiac disease prevention strategy

Introducing high doses of gluten from four months of age into infants' diets could prevent them from developing celiac disease, a study has found.

28 Sep 2020

Clover Biopharma's new trimeric subunit vaccine candidate prevents COVID-19 in monkeys

The vaccine candidate produced a high level of neutralizing antibodies in animal models. Rhesus macaques immunized with the vaccine candidate showed reduced viral loads in the lungs. The research is published on the preprint server bioRxiv.

28 Sep 2020

Anti-N-protein IgG may predict severity of COVID-19

A recent study by researchers at the University of Miami, Miami VA Healthcare System and Express Gene and published on the preprint server medRxiv in September 2020 reports on the prognostic significance of the anti-N Immunoglobulin G (IgG) antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

28 Sep 2020

Complex SARS-CoV-2 serology means universal immunological assay is not feasible

As we improve our understanding of immune responses and correlates of protection against the severe acute respiratory syndrome coronavirus (SARS-CoV-2), two UK researchers emphasize that we will probably utilize different assays to tackle specific questions. Their commentary is published in the prestigious journal Lancet Infectious Diseases.

27 Sep 2020

New trial tests combination antibody treatment for preventing COVID-19 illness

A combination antibody treatment for preventing COVID-19 illness in individuals who have had sustained exposure to someone with the virus is being studied by researchers at The University of Texas Health Science Center at Houston.

25 Sep 2020

Ultrapotent antibody mix locks infection machinery, inhibits SARS-CoV-2 attachment to cells

A mix of ultrapotent antibodies from recovered COVID-19 patients has been shown to recognize and lock down the infection machinery of the pandemic coronavirus and keep it from entering cells. Each of the antibody types performs these overlapping tasks slightly differently.

25 Sep 2020

Antibody News and Research

Further Reading

Researchers identify the target structures for T-cell response against SARS-CoV-2

SARS-CoV-2 D614G variant enhances infectivity, replication and transmission

Newly developed fusion protein could improve COVID-19 research

Researchers identify a new method to produce miniaturized antibodies

New graphical tool to identify potent neutralizing antibodies against SARS-CoV-2

Using new technology to study antibody responses in SARS-CoV-2-infected individuals

Self-collection of blood for COVID-19 antibody testing may be a reliable and easy alternative

Novel immunotherapy platform can connect mussel adhesive proteins to the antibodies

Antibody improves progression-free survival in patients with advanced prostate cancer

SARS-CoV-2 re-infection is real but rare: Case study

Cincinnati Children's research leads to approval of new drug for hypereosinophilic syndrome

New agreements to ensure all countries have fair access to COVID-19 rapid diagnostic tests

J&J's COVID-19 vaccine shows potent immune response in phase 2 human trial

Hamsters and ferrets clear low dose SARS-CoV-2 infection in 14 days

Early introduction of gluten may be an effective celiac disease prevention strategy

Clover Biopharma's new trimeric subunit vaccine candidate prevents COVID-19 in monkeys

Anti-N-protein IgG may predict severity of COVID-19

Complex SARS-CoV-2 serology means universal immunological assay is not feasible

New trial tests combination antibody treatment for preventing COVID-19 illness

Ultrapotent antibody mix locks infection machinery, inhibits SARS-CoV-2 attachment to cells

Antibodies eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo